Loading
Acasunlimab is an experimental bispecific antibody from Genmab in phase 3 trials for non-small-cell lung cancer, aimed at PD-L1.
Acasunlimab (GEN1046) is a bispecific antibody developed by Genmab. Its target is PD-L1 (the sponsor names PD-L1 x 4-1BB (CD137)). The sponsor states: Acasunlimab (GEN1046, DuoBody-PD-L1x4-1BB) is a bispecific antibody that co-targets PD-L1 and the costimulatory receptor 4-1BB, given intravenously in combination with pembrolizumab versus docetaxel in PD-L1-positive metastatic NSCLC that progressed after prior anti-PD-(L)1 therapy and chemotherapy. ClinicalTrials.gov describes the intervention as: Acasunlimab will be administered intravenously (IV). It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06635824 (Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)), in non-small-cell lung cancer. The largest, NCT06635824, plans to enrol 191 participants (actual) with primary completion expected 2027-07-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Acasunlimab (GEN1046, DuoBody-PD-L1x4-1BB) is a bispecific antibody that co-targets PD-L1 and the costimulatory receptor 4-1BB, given intravenously in combination with pembrolizumab versus docetaxel in PD-L1-positive metastatic NSCLC that progressed after prior anti-PD-(L)1 therapy and chemotherapy. Connects to PD-L1 and CD137 (4-1BB, TNFRSF9).
1.One arm of Acasunlimab binds PD-L1 on the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Acasunlimab" OR ABSTRACT:"Acasunlimab" OR TITLE:"GEN1046" OR ABSTRACT:"GEN1046" OR TITLE:"DuoBody®-PD-L1×4-1BB" OR ABSTRACT:"DuoBody®-PD-L1×4-1BB") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Acasunlimab, not a curated reading list.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares Genmab, Non-small-cell lung cancer and the tag pipeline.
Shares CD137 (4-1BB, TNFRSF9) and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.